COVID-SEROINDEX Trademark

Trademark Overview


On Monday, August 3, 2020, a trademark application was filed for COVID-SEROINDEX with the United States Patent and Trademark Office. The USPTO has given the COVID-SEROINDEX trademark a serial number of 90089958. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, May 31, 2022. This trademark is owned by Kantaro Biosciences LLC. The COVID-SEROINDEX trademark is filed in the Medical Instrument Products category with the following description:

Medical diagnostic apparatus for testing for viruses; Blood testing apparatus; Medical apparatus for collecting, processing and testing blood, bodily fluids, biological and cellular samples and specimens; Medical diagnostic instruments for the analysis of blood, body fluids, biological and cellular samples and specimens; Medical apparatus for analysis of biological materials, namely, blood, serum, plasma, bodily fluids, biological and cellular samples and specimens, for medical and clinical purposes; Medical apparatus and instruments for laboratory analysis, clinical diagnosis and treatment of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Tools and devices for medical diagnostics for detecting, measuring and analyzing DNA, RNA, genetic material, antibodies, enzymes, antigens, diseases, viruses and infections for medical, clinical and research purp...
covid-seroindex

General Information


Serial Number90089958
Word MarkCOVID-SEROINDEX
Filing DateMonday, August 3, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, May 31, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedical diagnostic apparatus for testing for viruses; Blood testing apparatus; Medical apparatus for collecting, processing and testing blood, bodily fluids, biological and cellular samples and specimens; Medical diagnostic instruments for the analysis of blood, body fluids, biological and cellular samples and specimens; Medical apparatus for analysis of biological materials, namely, blood, serum, plasma, bodily fluids, biological and cellular samples and specimens, for medical and clinical purposes; Medical apparatus and instruments for laboratory analysis, clinical diagnosis and treatment of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Tools and devices for medical diagnostics for detecting, measuring and analyzing DNA, RNA, genetic material, antibodies, enzymes, antigens, diseases, viruses and infections for medical, clinical and research purposes; Medical apparatus, instruments and devices for diagnostic use, namely, apparatus for medical diagnostic testing and analysis in the fields of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Medical test kits consisting primarily of probes, assays, reagents, media, solutions, buffers, antibodies, antigens, control materials, membranes, plasma, diagnostic chemicals, calibrators, swabs for medical purposes, plates, vessels, tubes, pipettes, trays, panels, slides, cards and bottles for testing for the presence of antibodies in blood, biological fluids, bodily fluids, biological and cellular samples and specimens and tissue; Medical diagnostic apparatus and devices for detecting, testing and analyzing blood, serum, plasma, bodily fluids, biological and cellular samples and specimens for DNA, RNA, genetic material, antibodies, enzymes, antigens, diseases, viruses and infections, all related to SARS-CoV-2 and COVID-19; Medical diagnostic apparatus for detecting infection; Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing; Biological sample containers for medical purposes, sold empty, namely, containers for the collection and preservation and transport of blood, biofluids, bodily fluids, biological and cellular samples and specimens obtained from humans and animals; all the foregoing related to the detection, diagnosis, testing, prevention and/or treatment of SARS-CoV-2, COVID-19 and antibodies, antigens, diseases, illnesses, viruses, disorders and/or infections related to SARS-CoV-2 or COVID-19

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, September 2, 2020
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKantaro Biosciences LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10036

Trademark Events


Event DateEvent Description
Tuesday, May 31, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, May 31, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Sunday, November 14, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Sunday, November 14, 2021FINAL REFUSAL E-MAILED
Sunday, November 14, 2021FINAL REFUSAL WRITTEN
Friday, August 27, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 20, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 20, 2021NON-FINAL ACTION E-MAILED
Saturday, March 20, 2021NON-FINAL ACTION WRITTEN
Friday, February 26, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, February 26, 2021NON-FINAL ACTION E-MAILED
Friday, February 26, 2021NON-FINAL ACTION WRITTEN
Wednesday, February 10, 2021ASSIGNED TO EXAMINER
Wednesday, September 2, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, August 6, 2020NEW APPLICATION ENTERED IN TRAM